| Document Date: 2014-05-30 12:01:38 Open Document File Size: 303,15 KBShare Result on Facebook
City Boston / Chicago / Waltham / Matrahaza / / Company Either Treatment Group / 2TESARO Inc. / AEs / HEC2 Control Conclusions / Table / / Country Hungary / United States / Italy / / Event FDA Phase / / Facility S.G. Moscati Hospital / Tufts Medical Center / University Teaching Hospital / / IndustryTerm control groups / rolapitant / control / prevention of CINV in cancer / / MedicalCondition Mediastinal Disorders / tumor / General Disorders / cancer / Nervous System Disorders / headache / Chemotherapy-Induced Nausea / neutropenia / nausea / Vomiting / fatigue / diarrhea / dizziness / constipation / Gastrointestinal Disorders / Nervous System Disorders General Disorders / skin and subcutaneous tissue disorders / / MedicalTreatment Chemotherapy / / Organization World Health Organization / C. Gridelli4 1Matrahaza Healthcare Center / S.G. Moscati Hospital / Medical Center / University Teaching Hospital / / / Position General / Breast Lung Colon/Rectum Head / Nervous System Disorders General / / Product Granisetron / Carboplatin / cisplatin / Dexamethasone / cytarabine / Cyclophosphamide / ifosfamide / Rescue Medication / HEC1 / Control Total Rolapitant / study drug / / ProvinceOrState Illinois / Massachusetts / / Region South Africa / / Technology Chemotherapy / /
SocialTag |